TICKERNERD
Menu
JNJJNJHealthcare · Drug Manufacturers - General

JNJ Stock Forecast: Johnson & Johnson Price Predictions for 2026-2027

Last close, 11 Sept 2026
$266
−0.29% on the day

The 23 Wall Street analysts covering Johnson & Johnson hold a median 12-month price target of $282 — +6.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$640.0B
Ticker Nerd rank
91 / 100
Median analyst target
$282
Analysts covering
23
Revenue$25.3B+6.6% y/y
Operating income$7.2B
Net income$5.5B
Free cash flow$7.3B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.6%
1M
+2.7%
YTD
+30.4%
1Y
+52.1%
From 52W high
−4.6%
From 52W low
+55.9%
$170
$278
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

JNJ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Johnson & Johnson on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Quality
95
Momentum
89
Issuance
88
Value
87
Revisions
64
Growth
63
Accruals
47
Size
0

Volatility (100): The share price has been relatively steady.

Accruals (47): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

JNJ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JNJ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300Oct 25Jan 26Apr 26Jul 26JNJHigh $320Median $282Low $190

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says23 analysts
16 Buy6 Hold1 Sell
Low $190Median $282High $320

The green dot is the last close — the median target sits +6.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HSBCMaintainsBuy$290 → $320
2 Sept 2026UBSMaintainsBuy$280 → $320
2 Sept 2026UBSMaintainsBuy—
6 Aug 2026GuggenheimMaintainsBuy—
6 Aug 2026GuggenheimMaintainsBuy$270 → $287
3 Aug 2026Wells FargoMaintainsOverweight$272 → $282
3 Aug 2026Wells FargoMaintainsOverweight—
17 July 2026GuggenheimReiteratesBuy—
17 July 2026GuggenheimReiteratesBuy$270
16 July 2026Morgan StanleyMaintainsOverweight$284 → $294
16 July 2026Morgan StanleyMaintainsOverweight—
16 July 2026Raymond JamesMaintainsOutperform—
16 July 2026Raymond JamesMaintainsOutperform$258 → $265
16 July 2026RBC CapitalReiteratesOutperform$287
16 July 2026RBC CapitalReiteratesOutperform—
16 July 2026Wells FargoMaintainsOverweight—
16 July 2026Wells FargoMaintainsOverweight$263 → $272
13 July 2026RBC CapitalMaintainsOutperform$265 → $287
13 July 2026RBC CapitalMaintainsOutperform—
13 July 2026TD CowenMaintainsBuy$250 → $300

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JNJ appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

JNJ vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Johnson & Johnson returned +52.1% against +17.5% for the S&P 500, dividends included.

JNJ vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Oct 25Jan 26Apr 26Jul 26JNJS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

JNJ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−4.5%
Analysts raising
0
Analysts cutting
4
Fundamentals

Johnson & Johnson (JNJ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.8×

Cheaper than 25% of US stocks

Price / sales
6.5×

Cheaper than 20% of US stocks

Price / book
7.5×

Cheaper than 13% of US stocks

EV / EBITDA
19.2×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
6.6%

Higher than 43% of US stocks

Earnings growth (YoY)
−0.1%

Higher than 35% of US stocks

Gross margin
68.2%

Higher than 81% of US stocks

Operating margin
29.2%

Higher than 87% of US stocks

Net margin
21.5%

Higher than 83% of US stocks

Returns & dividend
Return on equity
25.7%

Higher than 85% of US stocks

Return on assets
8.6%

Higher than 89% of US stocks

Dividend yield
2.0%

Higher than 45% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Johnson & Johnson (JNJ) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Johnson & Johnson has a market value of $640.0B and an enterprise value of $668.3B.

  • Revenue in the twelve months to 30 June 2026: $97.9B. The latest quarter grew 6.6% year on year.

  • Net income over the same four quarters: $21.0B, a 21.5% net margin.

  • Diluted earnings per share, trailing twelve months: $8.63.

  • Free cash flow in the twelve months to 30 June 2026: $22.2B, after $5.4B of capital spending.

  • Johnson & Johnson spent $8.1B on share buybacks and $12.6B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 2.4B.

  • Trailing P/E: 30.8×; forward P/E: 21.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.02%, paying out 61% of earnings.

  • Johnson & Johnson employs 138,200 people — $709K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

JNJ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
JNJJohnson & Johnson$640.0B
91
ABBVAbbVie, Inc.$454.3B
96
LLYEli Lilly & Co.$1.1T
90
MRKMerck & Co., Inc.$357.2B
82
AMGNAmgen, Inc.$203.4B
90
GILDGilead Sciences, Inc.$178.4B
93
PFEPfizer Inc.$157.6B
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Johnson & Johnson — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JNJ news & analysis

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

PRNewsWire · 14 Sept 2026positive

Johnson & Johnson announced results from the final overall survival analysis of the Phase 3 PAPILLON study, showing that first-line RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy delivered the longest reported median overall survival in patients with advanced non-small cell lung cancer with EGFR exon 20 insertion mutations, compared with chemotherapy alone.

Why it matters — The positive final survival data for RYBREVANT plus chemotherapy could strengthen JNJ's oncology portfolio by addressing a patient population historically facing poor outcomes with a low five-year survival rate.

J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion

WSJ · 12 Sept 2026neutral

J&J is in talks to sell its hips-and-knees business to Apollo for about $20 billion, according to WSJ. The health-products company said it planned to hive off its DePuy Synthes unit to focus on higher-growth areas.

Why it matters — The potential sale signals a strategic shift for J&J toward higher-growth areas of its portfolio, which is significant for investors tracking the company's direction.

The Closest Thing to Set-It-and-Forget-It Income: 5 Dividend Kings for Retirees Who Want Peace of Mind

24/7 Wall Street · 12 Sept 2026positive

The article highlights five companies, dubbed Dividend Kings, that have raised their dividends every year through recessions, pandemics, wars, and market crashes without missing a single year, positioning them as steady income plays for retirees. Johnson & Johnson is among the companies recognized for this consistent dividend growth record.

Why it matters — The piece reinforces JNJ's long-standing reputation as a reliable, uninterrupted dividend payer, which is relevant to investors focused on steady retirement income.

Apollo Global in talks to acquire J&J's orthopedics unit, Bloomberg News reports

Reuters · 11 Sept 2026neutral

Bloomberg News reported, citing sources, that Apollo Global Management is in discussions to acquire Johnson & Johnson's orthopedics unit in a deal that could value the unit at close to $20 billion. The report was published on Friday.

Why it matters — A divestiture of J&J's orthopedics business would represent a significant portfolio change for the company, potentially reshaping its medical devices segment.

3 Top Dividend Aristocrats To Own Near All-Time Highs

Zacks Investment Research · 11 Sept 2026positive

A Zacks Investment Research article highlights Johnson & Johnson among several Dividend Aristocrats, including Coca-Cola and Exxon Mobil, that are trading near all-time highs, reflecting bullish momentum driven by strong results or favorable operating conditions.

Why it matters — For JNJ watchers, this underscores the company's continued standing as a Dividend Aristocrat and its strong market performance near record levels.

FAQ

Frequently asked questions about JNJ stock

What is the JNJ stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Johnson & Johnson have a median 12-month price target of $282, with estimates ranging from $190 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JNJ stock a buy right now?

Of the 23 analysts covering Johnson & Johnson, 16 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Johnson & Johnson 91 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JNJ?

As at 12 Sept 2026, Johnson & Johnson ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will JNJ stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +6.2% from the last close, and Ticker Nerd's factor model ranks Johnson & Johnson 91 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JNJ stock forecast for 2030?

No analyst covering Johnson & Johnson publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JNJ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $190 to $320 over the next 12 months.

How has JNJ stock performed over the past year?

Johnson & Johnson returned +52.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Johnson & Johnson do?

Johnson & Johnson is a multinational healthcare company focused on Innovative Medicine and MedTech. Johnson & Johnson develops prescription medicines across areas such as immunology, oncology, neuroscience, cardiopulmonary disease, infectious disease, and metabolic disorders, while its MedTech business provides products and technologies for cardiovascular care, orthopedics, surgery, and vision.

What is the latest news on JNJ?

The most recent item we track (PRNewsWire, 14 Sept 2026): "Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer". Johnson & Johnson announced results from the final overall survival analysis of the Phase 3 PAPILLON study, showing that first-line RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy delivered the longest reported median overall survival in patients with advanced non-small cell lung cancer with EGFR exon 20 insertion mutations, compared with chemotherapy alone.

Company

About Johnson & Johnson.

Johnson & Johnson is a multinational healthcare company focused on Innovative Medicine and MedTech. Johnson & Johnson develops prescription medicines across areas such as immunology, oncology, neuroscience, cardiopulmonary disease, infectious disease, and metabolic disorders, while its MedTech business provides products and technologies for cardiovascular care, orthopedics, surgery, and vision. The company serves hospitals, healthcare professionals, pharmacies, and other care providers through a broad portfolio designed to support prevention, treatment, and minimally invasive procedures. Based in New Brunswick, New Jersey, Johnson & Johnson is a major participant in the global healthcare market, combining pharmaceutical research with medical technology to address a wide range of clinical needs across adult and specialty care.

CEO Mr. Joaquin Duato · 138,200 employees · United States · https://www.jnj.com